Objective To investigate the correlation between pre-treatment pan-immune inflam-mation value(PIV)and clinicopathological features in esophageal squamous cell carcinoma(ESCC)patients with postoperative adjuvant radiotherapy and evaluate its value in prognosis assessment com-bined with T stage.Methods A retrospective analysis was conducted on data of 85 ESCC patients with postoperative adjuvant radiotherapy in the Department of Radiation Oncology of the Affiliated Hospital of Yangzhou University from January 2019 to January 2023.The receiver operating character-istic(ROC)curve was drew to obtain the optimal cut-off value of PIV and other immune-inflammatory biomarkers.The area under the curve(AUC)and clinical applicability of PIV and other immune-in-flammatory biomarkers were compared based on the ROC curve and decision curve analysis(DC A).According to the optimal cut-off value,patients were divided into high PIV group and low PIV group,and the correlation between PIV level and clinicopathological features of ESCC was evaluated.Kaplan-Meier method was used for survival analysis,the Cox proportional hazards model was used for multivariate analysis,and a risk stratification model combining PIV and T stage was established by recursive partitioning analysis(RPA).Results The optimal cut-off value of pre-treatment PIV was determined as 187.22 based on the ROC curve.The AUC of PIV was 0.679,which was greater than 0.640,0.583,0.656 and 0.644 of the other four immune-inflammatory biomarkers such as the systemic immune-inflammation index(SII),platelet-to-lymphocyte ratio(PLR),monocyte-to-lymphocyte ratio(MLR),and neutrophil-to-lymphocyte ratio(NLR).The 85 patients were divided into low PIV group(＜187.22,n=48)and high PIV group(≥187.22,n=37).The level of PIV was significantly correlated with tumor diameter(P＜0.05).The 3-year overall survival(OS)(75.6％versus 30.6％,P＜0.001)and 3-year disease-free survival(DFS)(56.1％versus 21.0％,P＜0.001)were significantly higher in the low PIV group than the high PIV group.Tumor diameter,T stage and PIV were independent factors affecting OS in ESCC patients(P＜0.05),and T stage and PIV were independent factors affecting DFS in ESCC patients(P＜0.05).A new stag-ing system with three risk groups was established by the RPA stratification model based on T stage and PIV,which further improved the predictive value of prognosis compared with T stage or PIV alone.Conclusion Pre-treatment PIV is helpful in predicting the prognosis of ESCC patients with postoper-ative adjuvant radiotherapy,and the combination of PIV and T stage can improve the predictive value.

Pan-immune inflammation value(PIV)is a comprehensive immune inflammatory bio-marker based on complete blood cell counts,which has been proven to predict treatment response and survival outcomes for different types of tumors.However,the predictive value of the PIV varies in dif-ferent strategies for tumor treatment.This paper aims to systematically review the latest progress of PIV in predicting survival outcomes and tumor prognosis for immunotherapy,radiotherapy,targeted therapy,endocrine therapy,surgical treatment and neoadjuvant therapy,and analyze its existing challenges and issues,as well as look forward to its future development direction and application prospects.

Objective To investigate the correlation between pre-treatment pan-immune inflam-mation value(PIV)and clinicopathological features in esophageal squamous cell carcinoma(ESCC)patients with postoperative adjuvant radiotherapy and evaluate its value in prognosis assessment com-bined with T stage.Methods A retrospective analysis was conducted on data of 85 ESCC patients with postoperative adjuvant radiotherapy in the Department of Radiation Oncology of the Affiliated Hospital of Yangzhou University from January 2019 to January 2023.The receiver operating character-istic(ROC)curve was drew to obtain the optimal cut-off value of PIV and other immune-inflammatory biomarkers.The area under the curve(AUC)and clinical applicability of PIV and other immune-in-flammatory biomarkers were compared based on the ROC curve and decision curve analysis(DC A).According to the optimal cut-off value,patients were divided into high PIV group and low PIV group,and the correlation between PIV level and clinicopathological features of ESCC was evaluated.Kaplan-Meier method was used for survival analysis,the Cox proportional hazards model was used for multivariate analysis,and a risk stratification model combining PIV and T stage was established by recursive partitioning analysis(RPA).Results The optimal cut-off value of pre-treatment PIV was determined as 187.22 based on the ROC curve.The AUC of PIV was 0.679,which was greater than 0.640,0.583,0.656 and 0.644 of the other four immune-inflammatory biomarkers such as the systemic immune-inflammation index(SII),platelet-to-lymphocyte ratio(PLR),monocyte-to-lymphocyte ratio(MLR),and neutrophil-to-lymphocyte ratio(NLR).The 85 patients were divided into low PIV group(＜187.22,n=48)and high PIV group(≥187.22,n=37).The level of PIV was significantly correlated with tumor diameter(P＜0.05).The 3-year overall survival(OS)(75.6％versus 30.6％,P＜0.001)and 3-year disease-free survival(DFS)(56.1％versus 21.0％,P＜0.001)were significantly higher in the low PIV group than the high PIV group.Tumor diameter,T stage and PIV were independent factors affecting OS in ESCC patients(P＜0.05),and T stage and PIV were independent factors affecting DFS in ESCC patients(P＜0.05).A new stag-ing system with three risk groups was established by the RPA stratification model based on T stage and PIV,which further improved the predictive value of prognosis compared with T stage or PIV alone.Conclusion Pre-treatment PIV is helpful in predicting the prognosis of ESCC patients with postoper-ative adjuvant radiotherapy,and the combination of PIV and T stage can improve the predictive value.

Pan-immune inflammation value(PIV)is a comprehensive immune inflammatory bio-marker based on complete blood cell counts,which has been proven to predict treatment response and survival outcomes for different types of tumors.However,the predictive value of the PIV varies in dif-ferent strategies for tumor treatment.This paper aims to systematically review the latest progress of PIV in predicting survival outcomes and tumor prognosis for immunotherapy,radiotherapy,targeted therapy,endocrine therapy,surgical treatment and neoadjuvant therapy,and analyze its existing challenges and issues,as well as look forward to its future development direction and application prospects.